Sera Prognostics Adds Veteran Executive to Board
I'm LongbridgeAI, I can summarize articles.Sera Prognostics announced that Mark Capone, a veteran healthcare executive with experience at Myriad Genetics and Eli Lilly, will join its board of directors as a Class II director and Compensation Committee member effective July 1, 2026. This appointment aims to strengthen governance and commercial capabilities for the company's PreTRM test. While analysts rate the stock a Buy with a $6 target, TipRanks' AI analyst rates it Neutral due to weak financial performance despite a solid cash runway.
Sera Prognostics ( (SERA) ) has issued an update.
Sera Prognostics announced on June 30, 2026 that seasoned healthcare executive Mark Capone will join its board of directors as a Class II director and Compensation Committee member, effective July 1, 2026, with an initial term running through the 2029 annual meeting. Capone, a former CEO of Myriad Genetics and veteran of Eli Lilly, brings four decades of experience in molecular diagnostics, precision medicine and pharmaceutical commercialization, and will receive the company’s standard mix of cash and equity compensation for non-employee directors.
The appointment is intended to strengthen Sera’s governance and commercial capabilities as it works to expand adoption of its PreTRM test, which targets a significant unmet need in early prediction of preterm birth risk. Management highlighted Capone’s track record in scaling complex diagnostic platforms, navigating reimbursement and payer environments, and building high-performing commercial organizations as aligned with Sera’s next phase of growth and long-term strategy in the maternal and fetal health market.
The most recent analyst rating on (SERA) stock is a Buy
with a $6.00 price target.
To see the full list of analyst forecasts on Sera Prognostics stock,
see the SERA Stock Forecast page.
Spark’s Take on SERA Stock
According to Spark, TipRanks’ AI Analyst, SERA is a Neutral.
The score is held down primarily by very weak financial performance (minimal/declining revenue, negative gross profit, and sustained losses with ongoing cash burn). It is partially offset by a supportive earnings-call backdrop (cash runway through 2029 and cost-reduction/commercial progress) and neutral-to-mildly positive near-term technical signals, while valuation remains constrained by loss-making metrics and no dividend.
To see Spark’s full report on SERA stock,
click here.
More about Sera Prognostics
Sera Prognostics, Inc. is a health diagnostics company focused on precision pregnancy care, aiming to improve maternal and neonatal outcomes and reduce healthcare costs. Headquartered in Salt Lake City, it develops innovative diagnostic tests, including its flagship PreTRM test, a validated blood-based biomarker assay that assesses individualized risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
Average Trading Volume: 50,409
Technical Sentiment Signal: Sell
Current Market Cap: $70.49M